Health state utilities for relapsed or refractory large B-cell lymphoma treatments: a time trade-off study in the Japanese general population
{{output}}
Aim: Conventional therapies in Japan for relapsed or refractory large B-cell lymphoma (r/r LBCL) require intravenous infusion (IV), while epcoritamab is administered subcutaneously. Despite the expected quality of life (QOL) impr... ...
